Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Pharma Industry Analysis

UpdatedJun 08, 2026
DataAggregated Company Financials
Companies17
  • 7D3.5%
  • 3M-5.9%
  • 1Y21.4%
  • YTD1.5%

Over the last 7 days, the Pharma industry has risen 3.5%, driven by gains from AstraZeneca of 2.7%. Meanwhile, HUTCHMED (China) actually underperformed within the industry, shrinking 8.5% in the last week. This takes the industry's 12 month performance to a gain of 21%. Earnings are forecast to grow by 10% annually.

Industry Valuation and Performance

Has the U.K. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 09 Jun 2026UK£327.6bUK£92.3bUK£15.9b17.9x20.7x3.6x
Thu, 07 May 2026UK£320.8bUK£91.4bUK£15.7b17.8x20.4x3.5x
Sat, 04 Apr 2026UK£362.2bUK£91.4bUK£15.7b20x23x4x
Mon, 02 Mar 2026UK£370.6bUK£90.4bUK£15.6b22.7x23.8x4.1x
Wed, 28 Jan 2026UK£329.2bUK£88.3bUK£14.4b22x22.8x3.7x
Fri, 26 Dec 2025UK£323.1bUK£89.2bUK£14.6b21.8x22.2x3.6x
Sun, 23 Nov 2025UK£325.5bUK£90.6bUK£14.8b22.1x22x3.6x
Tue, 21 Oct 2025UK£298.0bUK£87.8bUK£11.7b20.6x25.4x3.4x
Thu, 18 Sep 2025UK£272.8bUK£87.0bUK£11.6b20.3x23.5x3.1x
Sat, 16 Aug 2025UK£275.6bUK£87.3bUK£11.7b21.9x23.6x3.2x
Mon, 14 Jul 2025UK£258.7bUK£86.5bUK£10.6b28x24.4x3x
Wed, 11 Jun 2025UK£272.5bUK£86.4bUK£10.6b27x25.7x3.2x
Fri, 09 May 2025UK£255.6bUK£87.5bUK£10.7b25.9x23.8x2.9x
Sun, 06 Apr 2025UK£266.5bUK£87.9bUK£9.7b30.7x27.4x3x
Tue, 04 Mar 2025UK£290.1bUK£88.5bUK£9.7b29.6x29.9x3.3x
Thu, 30 Jan 2025UK£239.2bUK£75.8bUK£7.8b33.3x30.5x3.2x
Sat, 28 Dec 2024UK£224.3bUK£75.3bUK£7.8b31.4x28.8x3x
Mon, 25 Nov 2024UK£224.7bUK£75.5bUK£7.8b31.3x28.8x3x
Wed, 23 Oct 2024UK£251.3bUK£72.5bUK£9.1b30.5x27.7x3.5x
Fri, 20 Sep 2024UK£256.1bUK£71.6bUK£8.9b38x28.6x3.6x
Sun, 18 Aug 2024UK£275.1bUK£72.6bUK£9.0b40.7x30.4x3.8x
Tue, 16 Jul 2024UK£256.3bUK£70.7bUK£9.4b32.4x27.1x3.6x
Thu, 13 Jun 2024UK£265.5bUK£71.2bUK£9.5b30.4x27.8x3.7x
Sat, 11 May 2024UK£273.5bUK£72.1bUK£9.6b37.4x28.4x3.8x
Mon, 08 Apr 2024UK£240.7bUK£70.8bUK£9.7b31.4x24.8x3.4x
Wed, 06 Mar 2024UK£234.3bUK£70.5bUK£9.7b30.8x24.1x3.3x
Fri, 02 Feb 2024UK£237.2bUK£69.5bUK£9.5b35.9x25x3.4x
Sun, 31 Dec 2023UK£235.0bUK£68.8bUK£10.7b35.5x22.1x3.4x
Tue, 28 Nov 2023UK£224.2bUK£69.2bUK£10.7b53.6x20.9x3.2x
Thu, 26 Oct 2023UK£237.7bUK£70.8bUK£10.4b55x22.9x3.4x
Sat, 23 Sep 2023UK£247.9bUK£70.4bUK£10.3b56.6x24x3.5x
Mon, 21 Aug 2023UK£234.0bUK£68.9bUK£10.2b53.5x23x3.4x
Wed, 19 Jul 2023UK£226.8bUK£66.8bUK£7.8b52x29.1x3.4x
Fri, 16 Jun 2023UK£250.6bUK£67.6bUK£7.9b55.5x31.8x3.7x
Price to Earnings Ratio

31.8x


Total Market Cap: UK£250.6bTotal Earnings: UK£7.9bTotal Revenue: UK£67.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Pharma Industry Price to Earnings3Y Average 25.3x202420252026
Current Industry PE
  • Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 20.7x which is lower than its 3-year average PE of 25.3x.
  • The industry is trading close to its 3-year average PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 26% per year over the last three years.
  • Revenues for these companies have grown 11% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?

GB Market-0.10%
Healthcare3.44%
Pharma3.54%
Pharma3.54%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AZN AstraZenecaUK£137.962.7%
+UK£5.6b		28.1%PE27.5x
GSK GSKUK£19.133.8%
+UK£2.8b		26.8%PE13.1x
HLN HaleonUK£3.311.3%
+UK£372.1m		-16.8%PE17.6x
HIK Hikma PharmaceuticalsUK£14.632.9%
+UK£87.3m		-30.8%PE10.3x
POLB Poolbeg PharmaUK£0.07920.4%
+UK£9.4m		125.7%PB6.5x

Latest News

AZN
UK£137.96
AstraZeneca
7D
2.7%
1Y
28.1%
FUM
UK£0.006
Futura Medical
7D
-14.5%
1Y
-93.8%
HIK
UK£14.63
Hikma Pharmaceuticals
7D
2.9%
1Y
-30.8%
STX
UK£0.06
Shield Therapeutics
7D
1.7%
1Y
133.0%
Narrative Update • Jun 05

STX: Pediatric And Japan Trial Milestones Will Drive Future Earnings Upside

Shield Therapeutics' analyst price target is now set at £0.14. Analysts attribute this level to unchanged fair value, discount rate and P/E assumptions, combined with modest adjustments to revenue growth and profit margin forecasts.
HLN
UK£3.31
Haleon
7D
1.3%
1Y
-16.8%
GSK
UK£19.13
GSK
7D
3.8%
1Y
26.8%
IMM
UK£0.045
ImmuPharma
7D
3.9%
1Y
68.2%
HCM
UK£1.65
HUTCHMED (China)
7D
-8.5%
1Y
-30.8%
Narrative Update • May 28

HCM: Late-Stage Hematology And Oncology Pipeline Will Drive Future Re-Rating Potential

Analysts have kept their fair value estimate for HUTCHMED (China) steady at £3.46 per share, with only marginal tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. Together, these factors support an unchanged price target narrative.
ANCR
UK£3.35
Animalcare Group
7D
0.9%
1Y
12.8%
POLB
UK£0.079
Poolbeg Pharma
7D
20.4%
1Y
125.7%
EAH
UK£0.93
ECO Animal Health Group
7D
-2.6%
1Y
46.8%
THAT
UK£0.0057
Thalia Therapeutics
7D
-11.5%
1Y
21.1%
AGY
UK£0.089
Allergy Therapeutics
7D
-6.7%
1Y
21.4%
NFX
UK£0.0017
Nuformix
7D
-11.3%
1Y
60.5%